Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 9/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 4/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17604614 | 0.77 | MAPK14 (0.46) | NPY5RKCNH2 | |
| SCHEMBL16095271 | 0.77 | NPY5R (0.34) | NPY5RKCNH2METAP2METAP1USP30 | |
| SCHEMBL16094449 | 0.76 | USP30 (0.36) | NPY5RKCNH2METAP2METAP1USP30 | |
| SCHEMBL16094913 | 0.76 | MAPK14 (0.39) | METAP2METAP1KDM4C | |
| SCHEMBL16095288 | 0.75 | KMT2A (0.43) | — | |
| SCHEMBL16033875 | 0.75 | NPY5R (0.38) | NPY5RKCNH2METAP2METAP1GRM5 | |
| SCHEMBL16095603 | 0.72 | LMNA (0.38) | METAP2METAP1KDM4C | |
| SCHEMBL16095454 | 0.72 | MAPK14 (0.41) | NPY5RKCNH2KDM4C | |
| SCHEMBL9792784 | 0.72 | NPY5R (0.45) | NPY5RKCNH2METAP2METAP1GRM5 | |
| SCHEMBL29500425 | 0.72 | NPY5R (0.45) | NPY5RKCNH2METAP2METAP1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3193881-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044342-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118720-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM3B | NPY5R 3750/4885KCNH2 2992/4885METAP2 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.